How is the robot sales of Gao Wei Group?

The world's first 5G robot-assisted laparoscopic surgery was completed in the Affiliated Hospital of Qingdao University. Doctors control the master hand and slave hand of the "Miaoshou" robot in Anshun, Guizhou, which is 3000 kilometers away, and synchronously remove tumors for patients. The surgical robot used in this remote surgery is a new generation of robotic surgery system independently developed by Gaowei Group. Not only has completely independent intellectual property rights, but also successfully obtained the first minimally invasive robot license in China. Compared with imported surgical robots, the "Miaoshou" robot not only has the characteristics of miniaturization and integration, but also can realize 540-degree end rotation of its mechanical arm, which not only accurately reproduces the doctor's surgical actions, solves the robot's complete set of technical problems, but also successfully breaks the foreign technology monopoly and greatly reduces the medical expenses of domestic patients.

1988, when Chen Xueli, 37, was the director of Tiancun Welfare Institute in Huancui District of Weihai City, he found that disposable infusion sets had a lot of business opportunities, so he borrowed 25,000 yuan from the tax office and founded a small medical device factory-Shandong Weihai Medical Polymer Products General Factory. At the beginning of the business, this small factory only produced disposable infusion sets, and later gradually produced syringes, blood transfusions, infusion needles and other products. With such low-value medical consumables, this small factory headed by Chen Xueli has developed rapidly.

Talent became the top priority of Gao Wei's development at that time. In the early 1990s, there was no national standard for disposable medical devices. Thanks to Chen Xueli's repeated efforts, Gao Wei "knocked" the door of cooperation between Shandong Institute of Medical Devices and Qingdao Ocean University, and built the first standardized production workshop of disposable infusion sets in China. So Chen Xueli got up the courage and plunged into the gate of Changchun Institute of Applied Chemistry, Chinese Academy of Sciences.

1999, Gao Wei Medical Polymer Research Center was established. In the following year, Yin Jinghua, then the director of the Polymer Application Research Office of the Institute, came to Gaowei as the chief engineer, creating a precedent for researchers to work in enterprises. The arrival of Yin Jinghua also directly gave birth to the localization of intravenous indwelling needle. Today, one out of every five intravenous indwelling needles in China comes from Gao Wei.

In Chen Xueli's view, Viagra has developed to this day, and innovation is ultimately embodied in products, but in fact it is embodied in ideology. With high-quality R&D team and huge R&D investment, Viagra not only upgraded the traditional infusion series products, but also established flexible and diverse cooperation methods and introduced experts in the fields of cardiac intervention, orthopedics and blood purification. And demand the productivity and added value of high-tech products.

From aiming at "domestic first-class" to "world-class". Driven by technological innovation, Viagra has established extensive technical alliances for many years, and established more than 30 R&D centers and joint laboratories in cooperation with domestic first-class scientific research institutions such as China Academy of Sciences and China Academy of Engineering. More than 65,438+000 academicians serve as enterprise technical consultants. In addition, Viagra also introduced a group of industry leaders through equity cooperation to jointly develop high-end products.

At one time, China's medical device industry even needed to import a needle from Japan. Now, adhering to the core values of "sincerity, loyalty and conscience", Gao Wei has developed from a township enterprise to the largest medical device manufacturer in China. At present, VIGAO has more than 200,000 varieties and specifications of medical devices and drugs 1000, and more than 500 patents/KLOC-0, including more than 400 invention patents, of which more than 30 were listed in national projects, and won 4 national scientific and technological progress awards and 2 national technological invention awards. 100 A variety of products broke foreign monopoly and saved the country more than 300 billion yuan. In 20021year, the sales revenue of Viagra exceeded 50 billion yuan. This achievement, in Chen Xueli's eyes, is the embodiment of firm innovation.

"Creating a healthy future with the White Messenger" has always been the corporate mission and social responsibility of Gaowei Group. As a national brand of medical device manufacturing industry, Gao Wei shoulders the heavy responsibility of actively implementing the healthy China strategy with practical actions. In the future, Gao Wei will continue to strengthen digital transformation, strengthen innovation drive and help Shandong develop with high quality.